At a DLB meeting, scientists reported progress in disentangling the notorious overlap in symptoms and pathology in this quintessential spectrum disease. (Hint: tangles are bad.)
Studies find that a drug in cough syrup can improve symptoms, and that radiation therapy safely shuts off a salivary gland.
At the International Dementia with Lewy Bodies conference in Fort Lauderdale, Florida, fuzzy images of dying sympathetic cardiac nerve terminals proved to be a sharp aide to clinch this notoriously difficult diagnosis.
At their international conference, DLB researchers demonstrated progress in defining a distinct identify for this Alzheimer’s-Parkinson’s overlap disease. This has helped prepare DLB for more therapeutics trials.
Trials of gene therapy for spinomuscular atrophy and stem cell treatments for ALS look promising.
Computerized assessments and electroencephalography both hold promise for diagnosis and drug testing in Alzheimer’s disease, but the Food and Drug Administration does not yet know how to oversee the technology.
In various animal models of traumatic brain injury, acute treatments quiet inflammation and preserve neurons and their myelin sheaths.
Researchers at this year’s SfN meeting detailed different strategies and outcomes of passive and active vaccines.
The leaders of two large European trials report that promoting cardiac health, exercise, and mental activity helped maintained cognition in older adults.
Forget transgenics for a moment. Large collections of inbred and outbred mice could be an untapped treasure trove for Alzheimer’s researchers.
At CTAD, investigational Phase 1 drugs include a repackaged and a new anti-amyloid, a tau vaccine, and a repurposed cancer drug.
At CTAD, a handful of candidate therapies were reported to have flamed out in Phase 2. They were unable to show efficacy. A new antipsychotic is entering the ring.
Several therapeutic approaches in Phase 3 reported updates at the CTAD conference earlier this month in Barcelona. Read about levetiracetam, deep brain stimulation, and scyllo-inositol.
The CTAD conference featured discussion among many scientists of how to measure a drug’s effect in pre-dementia patients who are so mildly impaired that established tools have trouble picking up improvement. Better cognitive tools are needed.
Both antibodies might be working, experts say, but the latest data released at the CTAD conference remain tantalizingly unclear. Trialists urgently need progression predictors and better outcome measures.